ArticleNature reviews. Cardiology2020
Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.
Article in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The Bidirectional Association Between Metabolic Syndrome and Long-COVID-19.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- ACE2-Inhibitory Effects of Bromelain and Ficin in Colon Cancer Cells.Medicina (Kaunas, Lithuania) · 2023Article
- Potential common mechanism of four Chinese patent medicines recommended by diagnosis and treatment protocol for COVID-19 in medical observation period.Frontiers in medicine · 2022Article
- Possible Beneficial Effects of Fresh Pomegranate Juice in SARS-CoV-2 Infection Conditions.Journal of nutrition and metabolism · 2022Review
- COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy.Health science reports · 2021Review
- Micronutrient therapy and effective immune response: a promising approach for management of COVID-19.Infection · 2021Review
- Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us?Current problems in cardiology · 2021Review
- COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Review
- Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions.Drug discovery today · 2021Article
- COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.Molecular biology reports · 2021Review
- Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19.Thrombosis and haemostasis · 2020Review
- Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.Clinical science (London, England : 1979) · 2020Review
- Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19.Hypertension (Dallas, Tex. : 1979) · 2020Article
- Approach to Acute Cardiovascular Complications in COVID-19 Infection.Circulation. Heart failure · 2020Review
- Covid-19: the renin-angiotensin system imbalance hypothesis.Clinical science (London, England : 1979) · 2020Review
- COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.Memorias do Instituto Oswaldo Cruz · 2020Article
- Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.